Product Description
For advanced solid tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04713891)
Mechanisms of Action: EP4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Keythera Pharmaceuticals (Australia)
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Bladder Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20211433 |
CTR20211433 | P1 |
Completed |
Squamous Cell Carcinoma|Esophageal Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Bladder Cancer |
2025-10-13 |
2025-11-09 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|